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Abstract
Several aggregation-prone proteins associated with neurodegenerative diseases can be modified by 
O-linked N-acetyl-glucosamine (O-GlcNAc) in vivo. One of these proteins, α-synuclein, is a toxic 
aggregating-protein associated with synucleinopathies, including Parkinson’s disease. However, 
the effect of O-GlcNAcylation on α-synuclein is not clear. Here, we use synthetic protein 
chemistry to generate both unmodified α-synuclein and α-synuclein bearing a site-specific O-
GlcNAc modification at the physiologically-relevant threonine residue 72. We show that this 
single modification has a notable and substoichiometric inhibitory-effect on α-synuclein 
aggregation, whilst not affecting the membrane binding or bending properties of α-synuclein. O-
GlcNAcylation is also shown to affect the phosphorylation of α-synuclein in vitro and block the 
toxicity of α-synuclein that was exogenously added to cells in culture. These results suggest that 
increasing O-GlcNAcylation may slow the progression of synucleinopathies and further support a 
general function for O-GlcNAc in preventing protein aggregation.
INTRODUCTION
O-GlcNAc modification (Fig. 1a) is the enzymatic addition of the single monosaccharide N-
acetyl-glucosamine to proteins in the cytosol, nucleus and mitochondria1,2. This 
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modification, which occurs on serine and threonine side-chains, is a uniquely dynamic form 
of glycosylation through the addition by the enzyme O-GlcNAc transferase (OGT) and 
removal by the enzyme O-GlcNAcase (OGA). Several lines of evidence link O-
GlcNAcylation to neurodegenerative diseases3,4. Neuron-specific knockout of OGT in mice 
results in locomotor defects, increased hyperphosphorylated tau, and death by 10 days after 
birth5. Several aggregation-prone proteins that directly contribute to neurodegeneration are 
themselves modified by O-GlcNAc, including tau6,7 and α-synuclein8,9. Increasing O-
GlcNAcylation in vivo using small-molecule inhibitors of OGA has been shown to reduce 
hyperphosphorylation of tau in healthy rats10 and slow neurodegeneration in a mouse model 
of Alzheimer’s disease11. Additionally, experiments where recombinant tau was 
enzymatically O-GlcNAcylated demonstrated that this modification can directly block that 
aggregation of tau in vitro11. Therefore, the maintenance of “normal” O-GlcNAcylation 
levels may be a protective mechanism that inhibits protein aggregation and is potentially lost 
in neurodegenerative diseases.
We are interested in examining the consequences of O-GlcNAcylation on α-synuclein, the 
aggregating protein in Parkinson’s disease and other synucleinopathies12. α-Synuclein is a 
140 amino-acid protein that is prevalent in pre-synaptic neurons of the central nervous 
system13. In the cytosol, the protein is an unfolded monomer, while it adopts an extended α-
helical conformation when associated with cellular membranes, where it performs its likely 
physiological roles in vesicle trafficking14. In contrast, in diseased cells, α-synuclein 
consists of β-sheet rich aggregates that are amyloid in structure (Fig. 1b)15. A range of 
aggregate-species that form in vitro closely resemble the aggregates in Parkinson’s disease 
brain-samples, biochemically supporting their importance in disease. Furthermore, recent 
experiments in human patients, animal models, and cell culture have shown that 
extracellular α-synuclein aggregates are toxic and that the protein is likely transferred from 
neuron-to-neuron where it can propagate disease pathology16–18. O-GlcNAc has been 
identified as an in vivo, endogenous modification of α-synuclein at threonine 64 and 72 in 
mice and serine 87 in humans, residues that are conserved between the species8,9,19, raising 
the possibility that O-GlcNAcylation may affect α-synuclein aggregation (Fig. 1c). In 
support of this hypothesis, we previously demonstrated that addition of synthetic peptides 
corresponding to fragments of the aggregation-prone region of α-synuclein (residues 61–95) 
will accelerate the in vitro aggregation of full-length protein20; however, the O-
GlcNAcylated peptides at threonine 72 (T72) do not have any effect on the kinetics of 
aggregation. Unfortunately, in the same study we also found that although recombinant tau 
is O-GlcNAcylated by OGT11,21, α-synuclein is not20. This is not necessarily surprising as 
OGT appears to require accessory proteins in order to modify some of its substrates22, but it 
does prevent the use of this method to study α-synuclein O-GlcNAcylation.
Here, we investigate the consequences of T72 O-GlcNAcylation on full-length α-synuclein. 
We selected T72 as our first target for O-GlcNAc modification since it has been identified in 
multiple proteomics experiments8,9 and because it lies within the region of α-synuclein that 
is required for aggregation in vitro (residues 71–82). First, we demonstrate that mutation of 
α-synuclein residue 72 to alanine (T72A), which would prevent O-GlcNAcylation at this 
position, dramatically reduces the aggregation of the protein. This would make any loss-of-
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function studies in cell culture or animals extremely difficult to interpret. To overcome this 
roadblock, we then used synthetic protein chemistry to generate site-specifically O-
GlcNAcylated α-synuclein at T72 for subsequent gain-of-function experiments. Comparing 
this protein to either synthetic, unmodified material or completely recombinant material, a 
well-accepted standard in the field of α-synuclein biochemistry, we show that the single O-
GlcNAc modification at T72 completely blocks the formation of both fiber and oligomer 
aggregates but has no effect on membrane binding or bending. We then demonstrate that O-
GlcNAcylation inhibits the toxicity of α-synuclein when it is exogenously added to neurons 
in culture. Since O-GlcNAcylation can affect subsequent phosphorylation, we also show that 
O-GlcNAcylation at T72 alters physiologically-relevant phosphorylation events on α-
synuclein by three different kinases. We further demonstrate that O-GlcNAcylation can act 
in a sub-stoichiometric fashion to slow α-synuclein aggregation. Finally, to explore the 
mechanism behind these observations, we find that O-GlcNAcylation primarily blocks 
aggregation by preventing the incorporation of α-synuclein into aggregates and thereby 
lowering the effective concentration of aggregation-prone material. These studies support an 
important role for O-GlcNAcylation in potentially inhibiting the progression of not only 
Alzheimer’s disease but Parkinson’s disease as well.
RESULTS
An α-Synuclein loss-of-function O-GlcNAcylation mutant has compromised aggregation
One common method to investigate the effects of posttranslational modifications in living 
cells or animal models is the expression of a loss-of-function point mutant of the protein of 
interest that cannot be endogenously modified. For example, the consequences of 
phosphorylation of α-synuclein serine 129 have been studied using a serine to alanine 
(S129A) mutation23. Therefore, one possibility to understand the role of O-GlcNAcylation 
would be overexpression of either wild-type or a T72A mutant protein and compare their 
effects in living cells. However, several studies have found that mutations in the region of α-
synuclein that is responsible for aggregation, including T72 to proline or glutamic acid, can 
themselves have dramatic effects on the aggregation of the protein24. Therefore, we 
recombinantly expressed both wild-type α-synuclein and the mutant protein α-
synuclein(T72A) (Supplemental Fig. S1) and subjected them to aggregation conditions (50 
μM protein concentration at 37 °C with constant agitation) for 4 days. To determine the 
extent of aggregation, a combination of thioflavin T (ThT) fluorescence and and 
transmission electron microscopy (TEM) were employed. Notably, we chose to use an end-
point-type assay, as the presence of ThT in continuous assays was recently shown to 
accelerate aggregation25. Analysis by fluorescence showed that wild-type protein aggregated 
with the expected kinetics beginning around 24 h, while α-synuclein(T72A) only displayed 
a small amount of ThT signal at 72 and 96 h (Supplementary Fig. S2). Analysis by TEM 
showed that both proteins form fiber structures of the expected diameter of ~10 nm 
(Supplementary Fig. S2). These data demonstrate that mutation of α-synuclein at T72 to 
prevent O-GlcNAcylation has a direct inhibitory effect on the aggregation of the protein, 
rendering any loss-of-function experiments by expression living cells impossible to 
accurately interpret.
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Synthesis of O-GlcNAcylated α-synuclein
Since the loss-of-function mutation (T72A) in α-synuclein itself inhibits aggregation, we 
chose to directly test the effects of O-GlcNAcylation at this residue by preparing the protein 
semi-synthetically by expressed protein ligation (EPL). The only absolute requirement for 
the semisynthesis of proteins using traditional EPL is a cysteine residue at any ligation sites. 
α-Synuclein contains no native cysteine residues, so we chose to introduce cysteines at 
residues 69 and 76, which are normally alanine residues in the native primary sequence. 
Introduction of these cysteine residues enables the retrosynthesis of α-synuclein (Fig. 2a) 
into a synthetic peptide (1, residues 69–75), a recombinant protein with an N-terminal 
cysteine residue (2, residues 76–140) and a recombinant protein thioester (3, residues 1–68). 
We reasoned that the introduced cysteines could be chemically desulfurized to alanine 
residues, yielding semisynthetic α-synuclein with no amino-acid mutations. As schematized 
in Fig. 2b, peptide 1 was prepared using standard Fmoc-based solid-phase peptide synthesis 
on the Dawson aminobenzyol resin that enables the generation of C-terminal peptide 
thioesters (Supplementary Fig. S3)26. Importantly, the N-terminal cysteine residue remained 
protected as a thioproline to prevent auto-ligation. Protein 2 was heterologously expressed in 
E. coli (Supplementary Fig. S4). Notably, we found that the initiating methionine-residue 
was conveniently removed during expression by an endogenous methionine aminopeptidase. 
Incubation of peptide 1 and protein 2 resulted in formation of the ligation product 4 in high 
yield (Supplementary Fig. S5). The new N-terminal cysteine residue of 4 was then 
deprotected by treatment with methoxylamine to give protein 5 (Supplemental Fig. S6). To 
prepare protein thioester 3, the appropriate α-synuclein fragment (residues 1–68) was 
recombinantly expressed as an N-terminal fusion with an engineered DnaE intein from 
Anabaena variabilis (Supplemental Fig. S7). Subsequent incubation of thioester 3 with 
protein 5 gave full-length, unmodified α-synuclein (Supplemental Fig. S8). Finally, radical-
based desulfurization was used to convert the two cysteine residues required for the ligations 
to the native alanine residues (synthetic α-synuclein, Fig. 2c and Supplemental Fig. S9).
We next embarked on the synthesis of α-synuclein bearing an O-GlcNAc modification at 
T72, which we termed α-synuclein(gT72). The synthesis followed the same route as that for 
unmodified α-synuclein with peptide 1 replaced by glycopeptide 7 (Fig. 3a). The selectively 
protected O-GlcNAcylated threonine residue was first synthesized using high-yielding 
thioglycoside chemistry20, followed by Fmoc-based solid phase peptide synthesis. On-resin 
deprotection of the O-GlcNAc moiety was accomplished using hydrazine before cleavage 
and purification of the glycopeptide by RP-HPLC (Supplementary Fig. S10). Notably, 
hydrazine-treatment did not result in any deprotection of the N-terminal cysteine residue. 
Following the same reaction scheme as in Fig. 2b, ~10 mg of α-synuclein(gT72) was readily 
prepared (Fig. 3a and Supplementary Fig. S11 – S14).
O-GlcNAcylation blocks α-synuclein aggregation but has no effect on membrane binding
Comparison of unmodified α-synuclein to α-synuclein(gT72) using circular dichroism 
revealed that O-GlcNAcylation does not result in the formation of any significant secondary 
structure (Supplementary Fig. S15), and dynamic light scattering showed no formation of 
oligomeric or aggregate structures during synthesis or purification (Supplemental Fig. S15). 
Recombinant α-synuclein, synthetic α-synuclein or α-synuclein(gT72) at a concentration of 
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50 μM were then simultaneously subjected to aggregation conditions for 7 days. After 72, 
120 and 168 h, reaction aliquots were removed and added to a solution of ThT. Analysis by 
fluorescence showed that recombinant and synthetic α-synuclein formed fibril aggregates; 
however, α-synuclein(gT72) resulted in no ThT fluorescence over the entire assay (Fig. 3b). 
To visualize the structure of any aggregates that formed, TEM was performed after 7 days. 
Both of the unmodified α-synuclein preparations formed protein-fibers characteristic of 
amyloidogenic proteins (Fig. 3c and Supplemental Fig. S16). In stark contrast, α-
synuclein(gT72) did not form any fibrous aggregates (Fig. 3c), as the only protein 
aggregates that we visualized by TEM were rare and amorphous in nature (Supplemental 
Fig. S17). To determine the relative amounts of protein that remained in solution after 7 
days of aggregation, we separated the insoluble and soluble fractions by centrifugation. The 
soluble fraction was then concentrated by lyophilization and both fractions were 
resuspended in 8M urea to break-up any aggregates. Analysis by SDS-PAGE showed that 
essentially all of the unmodified α-synuclein was incorporated into insoluble structures, 
while a large majority of α-synuclein(gT72) remained in solution (Fig. 3d). Next, we tested 
whether O-GlcNAcylation inhibits the formation of oligomeric structures that are also toxic. 
Protein samples that had been subjected to 7 days of aggregation were analyzed using SEC-
MALS (size exclusion chromatography with inline multi-angle light scattering), which 
enables the size determination of protein complexes (Fig. 3e). As expected, recombinant α-
synuclein formed oligomers that are very consistent in size with previous SEC-MALS 
experiments27,28. In contrast, α-synuclein(gT72) formed essentially no oligomeric species. 
Taken together, these data demonstrate that O-GlcNAcylation blocks the formation of both 
fibers and oligomers and promotes the solubility of α-synuclein under aggregation 
conditions.
α-Synuclein binds strongly to cellular membranes and negatively charged vesicles where it 
forms an extended α-helix29, and we have previously shown that α-synuclein can 
independently induce membrane curvature and convert vesicles into tubular structures in 
vitro30,31. Notably, the formation of small vesicles and tubes by α-synuclein has also been 
reported in vivo and in neuron culture32, and recent studies on the role of α-synuclein in 
synaptic vesicle endocytosis demonstrated that α-synuclein acts at the earliest stages of this 
process in neurons33. Together, these data establish membrane binding and bending as a 
relevant readout on the endogenous function of α-synuclein. To test whether O-
GlcNAcylation had any effect on these properties, recombinant α-synuclein or α-
synuclein(gT72) where incubated with a large excess (1:100) of membrane vesicles for 20 
min, and the extent of α-helix formation was measured using circular dichroism (Fig. 4a). 
As expected, recombinant α-synuclein formed an α-helix in the presence of negatively 
charged lipid vesicles (POPG or POPS) that could be competed by the addition of the 
zwitterionic lipid (POPC). Notably, we observed essentially no differences for α-
synuclein(gT72), which demonstrates that there are no significant changes in the affinity and 
mode of binding upon O-GlcNAcylation. Next, we incubated either recombinant α-
synuclein or α-synuclein(gT72) with POPG (1:20 ratio) for 20 min and found that both 
proteins induced the formation of tubular structures with a diameter of ~30 nm as visualized 
by TEM (Fig. 4b and Supplemental Fig. S18) Together, these data indicate that O-
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GlcNAcylation will likely have little to no effect on α-synuclein’s ability to bind or remodel 
membranes during its endogenous functions.
O-GlcNAcylation affects subsequent α-synuclein phosphorylation
In addition to its direct effects, O-GlcNAcylation has been demonstrated to affect 
phosphorylation of several substrate proteins. α-Synuclein is phosphorylated at multiple 
residues, including serine 87 (S87) and 129 (S129)23. Both of these phosphorylation sites 
have been shown to be closely associated with protein aggregates in vivo, indicating that 
they may have detrimental effects in PD. However, another model has emerged from a 
series of in vitro, cellular, and in vivo experiments that suggests a protective role for these 
phosphorylation events34–37. Briefly, these experiments showed that simultaneous 
phosphorylation at S87 and S129 by casein kinase 1 (CK1) can inhibit aggregation, and they 
demonstrated that polo-like kinases (PLKs) and G protein-coupled receptor kinase 5 
(GRK5) can phosphorylate α-synuclein aggregates an promote their degradation. Although 
the exact consequences of α-synuclein phosphorylation still need to be completely 
elucidated, we chose to test if O-GlcNAcylation affects these phosphorylation events. 
Recombinant α-synuclein or α-synuclein(gT72) were incubated with CK1, polo-like kinase 
3 (PLK3), or GRK5. The proteins were then separated by SDS-PAGE and analyzed by 
Western blotting (Supplementary Fig. S19). O-GlcNAcylation may have a small effect of 
increasing phosphorylation at S87 by CK1, while inhibiting the modification at S129 by all 
three kinases. It is therefore possible that O-GlcNAcylation of α-synuclein at T72 may not 
only directly block aggregation but also effect phosphorylation events that may play 
protective or detrimental roles in PD.
O-GlcNAcylation inhibits α-synuclein toxicity
Although O-GlcNAcylation blocks the formation of α-synuclein fibers and oligomers, it is 
possible that it does not inhibit the genesis of other insoluble or soluble species that are still 
toxic. α-Synuclein aggregates are found intracellularly in PD; however, many α-synuclein 
overexpression studies in neurons or cell-lines did not observe toxicity without additional 
cellular stress38–41. Additionally, we showed here that α-synuclein(T72A) has a intrinsic 
aggregation deficiency (Supplementary Fig. S2), which prevents the direct effects of O-
GlcNAcylation at this site to be meaningfully tested in an overexpression model. Notably, a 
growing body of evidence supports the extracellular, cell-to-cell transmission of α-synuclein 
aggregates to previously healthy neurons16,42. In particular, the exogenous addition of toxic 
α-synuclein-species to culture media results in the death of neurons and neuronal culture-
models, enabling us to directly test the effects of O-GlcNAcylation with our synthetic 
material. Accordingly, we initiated aggregation reactions containing recombinant α-
synuclein or α-synuclein(gT72). After 7 days, aggregates were first collected by 
centrifugation and then resuspended in culture media using sonication. To control for the 
presence of any species that remained soluble, the supernatant was concentrated by 
lyophilization and also resuspended in culture media. These samples (25 μM concentration 
based on monomer) were analyzed by TEM (Supplementary Fig. S20) and then added to 
either primary rat cortical neurons or SH-SY5Y cells, a neuroblastoma cell-line that 
expresses endogenous α-synuclein. After 60 h, cell toxicity was measured using the small-
molecule ethidium homodimer. Ethidium homodimer is an environmentally sensitive 
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fluorescent dye that excluded from healthy cells but gains access through the disrupted 
membranes of dying cells, where it intercalates into DNA. Recombinant α-synuclein 
aggregates caused a substantial increase in ethidium homodimer signal in both cell types 
(Fig. 5). In contrast, treatment with α-synuclein(gT72) resulted in no significant change in 
toxicity in neurons and less death in SH-SY5Y cells compared to unmodified protein (Fig. 
5). Notably, treatment of cells with either of the supernatants resulted in no significant 
changes in toxicity (Fig. 5). Because SH-SY5Y cells divide in culture, we also measured the 
effect of α-synuclein on their proliferation (Fig. 5). Consistent with the ethidium homodimer 
signal, unmodified α-synuclein aggregates inhibited proliferation, while α-synuclein(gT72) 
had no effect. Again, the soluble material from both proteins had no significant effect on 
proliferation (Fig 5). Together, these data indicate that α-synuclein O-GlcNAcylation 
prevents the formation of toxic species, and that it might slow the cell-to-cell spread of 
toxicity in the brain.
O-GlcNAcylation largely prevents incorporation of α-synuclein monomers into aggregates
To investigate how O-GlcNAcylation inhibits α-synuclein aggregation, we first asked if O-
GlcNAcylation has a substoichiometric effect on fiber formation. Aggregation reactions 
were prepared that contained either recombinant or synthetic α-synuclein, α-
synuclein(gT72) or different ratios of α-synuclein(gT72) and unmodified α-synuclein. 
Analysis by ThT fluorescence (Fig. 6a) demonstrated that as little as 10% O-GlcNAcylated 
α-synuclein resulted in delayed aggregation kinetics. Larger percentages (25 & 50%) 
increased this delay and yielded overall lower-levels of ThT fluorescence. Examination by 
TEM, showed that increasing percentages of O-GlcNAcylated did not have a noticeable 
effect on the structure of the fibers that were formed (Fig. 6b and Supplementary Fig. S21). 
The aggregation of α-synuclein is concentration dependent. Since, O-GlcNAcylation does 
not change the structure of the fibers formed, its sub-stoichiometric effect could be 
explained by the exclusion of α-synuclein(gT72) from the fibers, which would in effect 
simply lower the concentration of aggregation-competent protein. To test this possibility, 
aggregation reactions were initiated containing either unmodified α-synuclein at 50 μM, the 
same protein at 25 μM, or a 1:1 mixture of unmodified α-synuclein (25 μM) and α-
synuclein(gT72) (25 μM). Analysis of the aggregation kinetics by ThT fluorescence showed 
that aggregation was less efficient at 25 μM and in the 1:1 mixture compared to 50 μM α-
synuclein, with the 1:1 mixture showing slightly more aggregation at later time points (Fig. 
6c). Visualization of the aggregates by TEM again showed no major changes to the fiber 
structure (Fig. 6d and Supplementary Fig. S21). At the 168 h time point, aggregates from the 
25 μM and 1:1 reactions were isolated by centrifugation and the supernatant was 
concentrated by lyophilization. Both samples were dissolved in an 8M urea solution to break 
up any aggregates and then separated by SDS-PAGE. Western blotting showed that the vast 
majority of α-synuclein(gT72) remained in solution during the aggregation reaction 
(Supplementary Fig. S22), suggesting that a small fraction of α-synuclein(gT72) is 
incorporated into aggregates but the majority remains in solution. Finally, we tested whether 
O-GlcNAcylation inhibits the incorporation of α-synuclein monomers into a large amount of 
pre-formed fibers. Specifically, fibers were formed by subjecting unmodified α-synuclein to 
aggregation conditions for 7 days. At this time the fibers were sonicated to break the fibers 
and increase the available “ends” for elongation. They were then added to either buffer or 
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unmodified α-synuclein or α-synuclein(gT72) to give a mixture of 25 μM fibers and 25 μM 
monomeric protein. Aggregation conditions were then reinitiated and the extent of fiber 
formation was measured using ThT fluorescence (Supplementary Fig. S23). Fibers that were 
added to buffer gave relatively stable ThT fluorescence signal over the course of the 
experiment. In contrast, fibers mixed with unmodified α-synuclein yielded an immediate 
increase in ThT signal that plateaued within 24 h. Fibers mixed with α-synuclein(gT72) 
showed a similar increase in ThT signal with a small but statistically-significant decrease in 
the aggregation kinetics. Analysis of the aggregates that formed in these reactions by TEM 
(Supplementary Fig. S23) showed that addition to unmodified α-synuclein formed long, 
straight fibers of ~10 nm in diameter, while those formed by α-synuclein(gT72) are 
somewhat more irregular in shape, suggesting that O-GlcNAcylation may have an effect on 
the structure of the fibers when it is incorporated into them. Together, these three 
experiments indicate that O-GlcNAcylated α-synuclein remains more soluble during the 
aggregation reaction and is incorporated at a reduced efficiency compared to unmodified α-
synuclein; however, this equilibrium between soluble and aggregated α-synuclein(gT72) can 
be driven by the presence of a large amount of pre-formed, unmodified fibers. 
(Supplementary Fig. S24).
DISCUSSION
Here, we used synthetic protein chemistry to show that site-specific O-GlcNAcylation of α-
synuclein at T72 inhibits protein aggregation by most-likely shifting the equilibrium of the 
aggregation reaction towards soluble material. Although there is currently no atomic-scale 
structural information about α-synuclein aggregates, our data is consistent with experiments 
using electronic spin resonance (EPR)43 and solid-state NMR44 spectroscopies, which 
demonstrate that T72 lies in the core of a fiber. O-GlcNAcylation also inhibits the toxicity of 
α-synuclein in a well-established extracellular assay when added to primary neurons or a 
neuronal cell-line. We believe that this difference probably results from both a reduction in 
the direct toxicity of aggregates in culture and reduced uptake of the protein, as aggregates 
have been shown to be endocytosed more efficiently than monomeric protein16. In contrast 
to the inhibition of aggregation by O-GlcNAcylation, the modification does not interfere 
with membrane binding or bending by α-synuclein, indicating that it would not disrupt the 
normal biological functions of the protein. This has important implications for 
neurodegenerative diseases. OGA inhibitors that raise O-GlcNAcylation levels should be 
pursued as possible therapeutics in both Alzheimer’s disease and synucleinopathies, 
particularly in cases where genetic screening can inform early treatment decisions to 
potentially slow the onset of protein aggregation. Coupled with previous data on the 
aggregation prone proteins tau and TAB111, as well as recent evidence that O-GlcNAc 
prevents the aggregation of the Polycomb protein Polyhomeotic (Ph) in Drosophila45, these 
data add further support to a model where O-GlcNAcylation prevents indiscriminate protein 
aggregation in general. Finally, we also found that a T72A mutant of α-synuclein that would 
prevent O-GlcNAcylation has a large effect on the aggregation of α-synuclein, preventing 
the straight-forward interpretation of any loss-of-function experiments [e.g., over-expression 
of wild-type α-synuclein and α-synuclein(T72A) in cell culture or animal models]. This 
highlights the unique utility of synthetic protein chemistry to investigate the direct effects of 
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posttranslational modifications on proteins, including modification of α-synuclein by O-
GlcNAcylation (this study), ubiquitination46,47, phosphorylation,48, acetylation49, and 
nitration50.
METHODS
Methods and any associated references are available in the online version of the paper.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. O-GlcNAc modification and α-synuclein
a, O-GlcNAc modification (O-GlcNAcylation) is a dynamic modification of intracellular 
proteins by the monosaccharide N-acetyl-glucosamine (GlcNAc). b, The protein α-synuclein 
forms toxic amyloid-aggregates that contribute to the progression of neurodegenerative 
diseases, including Parkinson’s disease. α-Synuclein is O-GlcNAcylated at three different 
sites but the effects on protein aggregation and toxicity were unknown. Here, we determine 
the consequences of O-GlcNAcylation at threonine residue 72.
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Figure 2. Semisynthesis of α-synuclein
a, α-Synuclein was retrosynthetically deconstructed into a synthetic thioester-peptide (1), a 
recombinant protein (2) and a recombinant protein thioester (3) obtained using intein 
chemistry. b, Synthetic scheme outlining the preparation of α-synuclein. Synthetic thioester-
peptide 1 was first incubated with recombinant protein 2, resulting in the ligation reaction 
that yielded protein 4. The N-terminal thioproline of 4 was then transformed to the 
corresponding cysteine (5) by treatment with methoxylamine. Protein 5 was then ligated to 
the protein thioester 3 to give full-length α-synuclein. The cysteines required for the ligation 
reactions were then desulfurized to the native alanine residues to give synthetic α-synuclein 
with no amino acid mutations. (c) Characterization of synthetic α-synuclein using RP-HPLC 
and ESI-MS. Analysis by RP-HPLC showed that synthetic α-synuclein was pure, as 
evidenced by the appearance of only one, sharp peak. Characterization by ESI-MS gave a 
range of charge-states that could be deconvoluted to a molecular mass (14,460 ± 3 Da) in 
excellent agreement with the predicted weight of 14,460 Da.
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Figure 3. O-GlcNAcylation blocks α-synuclein aggregation
a, α-Synuclein bearing an O-GlcNAc modification at threonine 72 [α-synuclein(gT72)] was 
prepared using the same semisynthetic route outlined in Fig. 2b by replacing peptide 1 with 
glycopeptide 7. Analysis of purified α-synuclein(gT72) by RP-HPLC showed only one, 
sharp peak. Characterization by ESI-MS gave a range of charge-states that could be 
deconvoluted to a molecular mass (14,667 ± 2 Da) in good agreement with the predicted 
weight of 14,663 Da. b, O-GlcNAcylation blocks α-synuclein fiber formation. Recombinant 
α-synuclein or synthetic α-synuclein or α-synuclein(gT72) (50 μM) were subjected to 
aggregation conditions (agitation at 37 °C) before analysis by ThT fluorescence (λex = 450 
nm, λex = 482 nm) at the indicated time points. y-Axis is fold-change in fluorescence 
compared to recombinant α-synuclein at t = 0 h. Results are the mean ±s.e.m. of three 
separate experiments. Both recombinant and synthetic α-synuclein give strong ThT 
fluorescence signals over the course of the aggregation assay, while α-synuclein(gT72) 
results in no detectable increase in the signal. c, The same reactions were analyzed by TEM 
after 7 days; scale bar: 500 nm. Mature, rigid fibers with an approximate diameter of 10 nm, 
consistent with amyloid structures, were readily visualized in the recombinant and synthetic 
α-synuclein aggregation reactions, but were completely lacking in the α-synuclein(gT72) 
reaction. d, The majority of α-synuclein(gT72) remains soluble during aggregation. After 7 
days, aggregation reactions were also separated by centrifugation, resuspended in 8M urea 
to disassociate any aggregates, and analyzed by SDS-PAGE and coomassie staining. 
Essentially all of the recombinant α-synuclein formed insoluble aggregates, while the 
majority of α-synuclein(gT72) was found in the soluble fraction. e, O-GlcNAcylation blocks 
α-synuclein oligomer formation. Aggregation reactions were analyzed by SEC-MALS after 
7 days. Faster eluting peaks corresponding to molecular weights of approximately 1,000 and 
100 kDa were detectable in the recombinant α-synuclein aggregation reaction, but were 
essentially absent in the α-synuclein(gT72) reaction.
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Figure 4. O-GlcNAcylation has no effect on α-synuclein membrane binding or bending
a, O-GlcNAcylation has no effect on α-synuclein α-helix formation upon membrane 
binding. Recombinant α-synuclein or α-synuclein(gT72) were incubated with an 100-fold 
excess of the indicated, preformed vesicles and analyzed using circular dichroism (CD). In 
the presence of negatively charged vesicles (POPG or POPS), both recombinant α-synuclein 
amd α-synuclein(gT72) gave indistinguishable CD spectra consistent with the formation of 
an extended α-helix. The introduction of a zwitterionic lipid (POPC) reduced the α-helix 
formation equally for both proteins. b, Unmodified α-synuclein and α-synuclein(gT72) bend 
membranes into tubules equally. Recombinant α-synuclein or α-synuclein(gT72) were 
incubated with a 20-fold excess of POPG vesicles and analyzed using TEM. Both proteins 
remodeled the vesicles into tube structures of approximately 30 nm in diameter. POPG = 1-
palmitoyl-2-oleoyl-sn-glycero-3-[phospho-RAC-(1-glycerol)]; POPS = 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine; POPC = 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine.
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Figure 5. O-GlcNAcylation blocks α-synuclein toxicity
Primary rat cortical neurons in culture or SH-SY5Y cells were treated for 60 h with vehicle 
or insoluble material or remaining soluble material (25 μM based on monomer 
concentration) collected from aggregation reactions initiated with either α-synuclein(gT72) 
or recombinant α-synuclein. In both cell types, toxicity was measured with ethidium 
homodimer fluorescence (λex = 528 nm, λex = 617 nm). Treatment with recombinant α-
synuclein resulted in significantly more toxicity than α-synuclein(gT72) in both cells types 
tested. Cellular proliferation was measured in SH-SY5Y cells by cell counting. Again, 
treatment with recombinant α-synuclein slowed cellular proliferation to a significantly 
larger extent than α-synuclein(gT72). Results are the mean ±s.e.m. of three separate 
experiments. Statistical significance (two-tailed, t-test): *P < 0.05, **P = < 0.01.
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Figure 6. O-GlcNAcylated α-synuclein is largely excluded from the protein aggregates
a, Recombinant α-synuclein or synthetic α-synuclein (50 μM) or the indicated mixtures of 
α-synuclein(gT72) and recombinant α-synuclein (50 μM total concentration) were subjected 
to aggregation conditions (agitation at 37 °C) before analysis by ThT fluorescence (λex = 
450 nm, λex = 482 nm) at the indicated time points. y-Axis is fold-change in fluorescence 
compared to recombinant α-synuclein at t = 0 h. Increasing percentages of α-
synuclein(gT72) compared to recombinant α-synuclein resulted in slower aggregation 
kinetics and lower overall ThT fluorescence levels. b, The same reactions were analyzed by 
TEM after 7 days; scale bar: 500 nm. Increasing percentages of α-synuclein(gT72) 
compared to recombinant α-synuclein resulted in the formation of fewer overall fiber 
structures but did not change the gross structures of the fibers formed. c, Recombinant α-
synuclein at 50 μM or 25 μM or a 1:1 mixture of recombinant α-synuclein (25 μM) and α-
synuclein(gT72) (25 μM) were were subjected to aggregation conditions (agitation at 37 °C) 
before analysis by ThT fluorescence (λex = 450 nm, λex = 482 nm) at the indicated time 
points. y-Axis is fold-change in fluorescence compared to recombinant α-synuclein at t = 0 
h. The 1:1 mixture of recombinant α-synuclein and α-synuclein(gT72) (50 μM 
concentration) gave less aggregation than α-synuclein alone but more than recombinant α-
synuclein at a concentration of 25 μM. d, The same reactions were analyzed by TEM after 7 
days; scale bar: 500 nm. All three aggregation reactions formed fibers that were similar in 
structure and size. All results are the mean ±s.e.m. of at least three separate experiments. 
Statistical significance (two-tailed, t-test): *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001.
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